Alzheimer’s disease is a debilitating neurodegenerative disease and the most common form of dementia. Symptoms include irritability, confusion, mood swings, language difficulties and memory loss. Cognitive dysfunction becomes more pronounced as the disease progresses, leading to the loss of bodily functions and eventually death.
Alzheimer’s disease is characterized by the presence of amyloid plaques in the brain. Soluble beta-amyloid (Abeta) oligomers are thought to underlie the cognitive deficits associated with Alzheimer’s disease. Cognition Therapeutics therapies pharmacologically compete with Abeta oligomers for critical receptor targets preventing synapse loss and improving memory and their small molecule therapeutics act through molecular targets that have not been previously implicated in Alzheimer’s disease.
Cognition Therapeutics has received a US patent that describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer's disease. Disease-relevant screening technologyclosely models the pathology of neurodegenerative diseases and novel, high-quality CNS-biased chemical libraries. These platforms can predict behavioral efficacy of candidate drugs in Alzheimer's models. U.S. National Stage Application: No. 13/263,162, entitled "Inhibitors of Cognitive Decline" was filed on October 6, 2011.
CogRx CEO Hank Safferstein said, "The allowance of this patent demonstrates the strength of Cognition Therapeutics's intellectual property and high-level recognition that its technologies are both relevant and of great value to the therapy and ultimate conquering of Alzheimer's disease."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Sexual Fantasies: Threesomes Are Normal, Golden Showers Not So Much
- Ghost Light From Dead Galaxies - A Hubble Halloween
- Mediterranean Diet Linked To Better Kidney Health
- US Wildlife Bans On GMOs And Neonics Lack Transparency And Scientific Rationale
- Greenpeace Says Its GMOs Are Better Than Science's GMOs, Still Hates Golden Rice
- Cyclone Nilofar Looks More Like A Comet
- Game Theory: When Are Groups Social? Or Insufferable?
- "well, since Soylent Green is people, that probably explains it...."
- "*Low* out-of-pocket payments for health care is precisely why health care is so expensive. Approximately..."
- "Always love reading your articles Hank :) and any knowledgeable person about science knows what..."
- "Ah - sorry, but regardless that this may be taken as disdain again by you, you seem to simply have..."
- "Twelve years in a major urban public school system, and I couldn't once bring myself to eat a school..."
- Anti-GMO bungle: Claim GM genes pass from food into blood collapses
- GLP Infographic: Is labeling GMOs really about our “Right to Know”?
- Battle of Britain: NGOs and scientists clash over proposal to loosen EU GMO restrictions
- Genetically modified clean energy from bacteria
- Designer babies: You can screen for cystic fibrosis but intelligence is a ways off
- Science as profane: What superstition of 1752 and 2014 share in common
- Report examines health care challenges for pregnant women enrolled in covered California
- NYU research: Majority of high school seniors favor more liberal marijuana policies
- ESA Frontiers November preview
- Sexual fantasies: Are you normal?
- Synthetic lethality offers a new approach to kill tumor cells, explains Moffitt researcher